Formulation and Liponiosomal Hydrid Delivery System Containing Anti-Diabetic Drug Rosiglitazone

References

[1] Nagalakshmi S, Kalaiapurmal K, Arul Jothy M, Chaudhari PS, Pushpalatha HB, Shanmuganthan S. Fabrication and Characterization of Herbal Drug –Loaded Nonionic Surfactant Based Niosomal Topical Gel. J Pharm Sci Res 2016; 8(11): 1271-1278.

[2] Parhizkar M, Reardon PJT, Harker AH, Browning RJ, Stride E, Pedley RB, Knowles JC, Edirisinghe M. Enhanced efficacy in drug-resistant cancer cells through synergistic nanoparticle mediated delivery of cisplatin and decitabine. Nanoscale Adv 2020; 2: 1177-1186. RSC

[3] Bhagwat RR, Vaidhya IS. Novel drug delivery systems: An overview. Int J Pharm Sci Res 2013; (3): 970-982.

[4] Gurjar P, Naik N, Chouksey S. Niosome: A Promising Pharmaceutical Drug Delivery. Int J Pharmaceut Drug Anal 2014; 2(5): 425-431.

[5] Dave V, Sharma S, Yadav RB, Agarwal U. Herbal liposome for the topical delivery of ketoconazole for the effective treatment of seborrheic dermatitis. Appl Nanosci 2017; 7: 973-987. Springer

[6] Sharma A (1997) Liposomes in drug delivery: progress and limitations. Int J Pharm 154:123–140.

[7] Lasic DD. Liposomes: From Physics to Applications. Elsevier: New York, Chap. 1-3; 1993.

[8] Janoff AS. Liposomes: Rational Design. Marcel Dekker, New York, Chap. 1; 1998.

[9] Berestein GL, Fuller IJ. Liposomes in the therapy of infectious diseases and cancer. New York Press; 1989.

[10] Ostro MJ. Liposomes: From biophysics to therapeutics. Marcel Dekker, New York; 1987.

[11] Armann C, Roding J, Ghyczy M, Pratzel HG. Liposomes from soya phospholipids as percutaneous drug carriers. Arzneim-Forsch/ Drug Res 1990; 40: 1365-1368.

[12] Hamilton RL, Guo L. Preparation, properties and potential. In Liposome Technology, Vol. 1, CRC Press, Fl; 1984.

[13] De Gier J, Mandersloot JG, Van Deenen LLM. Lipid composition and permeability of liposomes. Biochim Biophys Acta 1968; 150: 666-675.

[14] Gharbavi M, Amani J, Kheiri-Manjili H, Sharafi A. Niosome: A promising nanocarrier for natural drug delivery through blood-brain barrier. Adv Pharmacol Pharm Sci 2018.

[15] Muzzalupo R, Tavano L. Niosomal drug delivery for transdermal targeting: recent advances,” Res Reports Transdermal Drug Del 2015; 4: 23–33. Taylor & Francis

[16] Yeo PL, Lim CL, Chye SM, Ling APK, Koh RY. Niosomes: a review of their structure, properties, methods of preparation and medical applications. Asian Biomed 2007; 11(4): 301-314.

[17] Kazi KM, Mandal AS, Biswas N, Guha A, Chatterjee SA, Behera M, et al.

[18] Keservani RK, Sharma AK, Ayaz Md, Kesharwani RK. Novel drug delivery system for the vesicular delivery of drug by the niosomes. Int J Res Controlled Release. 2011; 1: 1–8.

[19] Khandare JN, Madhavi G, Tamhankar BM. Niosomes novel drug delivery system. The Eastern Pharmacist. 1994; 37: 61–64.

[20] Verma AK, Bindal JC. A vital role of niosomes on controlled and novel drug delivery. Indian J Novel Drug Deliver. 2011; 3: 238–246.

[21] Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: a controlled and novel drug delivery system. Biol Pharm Bull. 2011; 34: 945–593.

[22] Tarekegn A, Joseph NM, Palani S, Zacharia A, Ayenew Z. Niosomes in targeted drug delivery: some recent advances. Int J Pharm Sci Res 2019; 1(9-S).1-8.

[23] Chomchoey S, Klongdee S, Peanparkdee M, Klinkesorn U. Fabrication and characterization of nanoemulsions for encapsulation and delivery of vitexin: antioxidant activity, storage stability and in vitro digestibility. Journal of the Science of Food and Agriculture. 2022; Wiley

@article{1723250,
      author = {Avinash Dhakad, Dr. Pradeep Chauhan, Dr. Sandeep Jain, Dr. Bharat K. Tyagi},
      title = {Formulation and Liponiosomal Hydrid Delivery System Containing Anti-Diabetic Drug Rosiglitazone},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {3},
      pages = {2169-2176},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1723250.pdf},
      abstract = {Rosiglitazone is a thiazolidinedione antidiabetic drug used in the management of type 2 diabetes mellitus. The present study aimed to formulate and evaluate a liponiosomal hybrid drug delivery system containing rosiglitazone to improve drug entrapment and provide controlled drug release. The formulation was developed using suitable lipid, non-ionic surfactant, and cholesterol components and optimized based on physicochemical characteristics. The prepared formulations were evaluated for particle size, polydispersity index, zeta potential, drug entrapment efficiency, morphology, drug–excipient compatibility, and in vitro drug release. The developed liponiosomal system is expected to provide enhanced drug encapsulation and sustained release of rosiglitazone, indicating its potential as an advanced delivery approach for antidiabetic therapy.},
      keywords = {Rosiglitazone, Liponiosomes, Hybrid drug delivery system, Antidiabetic drug, Nanocarrier, Controlled drug release, Drug entrapment efficiency, Lipid-based drug delivery.},
      month = {September},
  }